Sail Biomedicines

Sail Biomedicines, founded in 2021 and backed by Flagship Pioneering, is developing a next-generation RNA therapeutics platform designed to overcome key limitations of conventional mRNA. Its core technology integrates three components: eRNA for prolonged protein expression, programmable TNPs for cell-specific delivery beyond the liver, and proprietary AI algorithms to accelerate drug design. The company is in the preclinical stage, building a pipeline focused on chronic and genetically defined diseases with high unmet need.

Integrated platform combining Endless RNA (eRNA) for durable protein expression, Targeted Nanoparticles (TNPs) for cell-specific delivery, and proprietary generative AI for integrative drug design.

Sail competes in the crowded next-generation RNA therapeutics space, facing companies developing improved LNPs, other circular RNA platforms, and alternative delivery technologies. Its differentiation lies in the integrated combination of durable RNA, programmable delivery, and AI-driven design.